GlassScriptPhysician profile
Satinder Kumar Aggarwal
NPI 1700862034
$8,476.00
in general payments reported to CMS, 2019-2025
45 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $172 · 2021: $1,520 · 2022: $1,963 · 2023: $1,650 · 2024: $1,744 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,821.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $994.17 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $785.88 | 2021-2025 | Vraylar, Linzess, Qulipta |
| Novo Nordisk INC | $764.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $625.73 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $547.75 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $421.26 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $366.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $340.86 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $327.44 | 2022-2024 | Verquvo, Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $318.73 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $288.38 | 2021-2025 | Rexulti, Abilify Mycite |
| Teva Pharmaceuticals USA, INC. | $241.44 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Amarin Pharma, INC. | $220.47 | 2020-2022 | |
| Dexcom, INC. | $206.57 | 2021-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $179.55 | 2023-2025 | Gemtesa |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satinder Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.